ClinicalTrials.gg
Active, not recruitingNCT04458324Updated Oct 16, 2026

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

A Phase 2 interventional study of Buspirone Hydrochloride and Buspirone placebo in Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Spaulding Rehabilitation Hospital · Phase 2, Interventional, and Prevention

How we know

Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital — 3 open to participants now, 8 under way, none of them phase 3. Spinal Cord Injuries · Spaulding Rehabilitation Hospital.

Planned enrollment
3rd of 25
70 · median 24
Started
2020
with 2 others
Phase 2
3 of 25
none open now
Registered
16th of 25
by date

Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2020, is one of 3 in phase 2, and was the 16th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, or all of them as a file.
02

Study summary

Over the past ten years, the Cardiovascular Research Laboratory at Spaulding has refined a unique form of exercise for those with spinal cord injuries (SCI). Functional Electrical Stimulation Row Training (FESRT) couples volitional arm and electrically controlled leg exercise, resulting in the benefits of large muscle mass exercise. However, despite the potential for enhancing aerobic capacity by training the denervated leg skeletal muscle via hybrid FES exercise, the inability to increase ventilation beyond limits set by high level SCI restricts aerobic capacity.

This research study will investigate two potential methods of improving ventilation in those with high-level SCI through a double-blind randomized trial. One method is non-invasive ventilation (NIV), which is an external breathing support machine. The second method is the use of Buspar, a drug, which has been used to treat respiratory dysfunction after SCI in rats and some human case reports.

In this study, participants will engage in a 6-month FES row training program while receiving either NIV or shamNIV and Buspar or placebo, and under study tests to evaluate cardiopulmonary health and fitness.

Read the detailed description

Regular aerobic exercise with sufficient intensity can improve overall health, however daily energy expenditure is low in those with SCI, especially in those with high level lesions. The investigators have developed Functional Electrical Stimulation Row Training (FESRT) that couples volitional arm and electrically controlled leg exercise, increasing the active muscle and resulting in benefits of large muscle mass exercise. Despite the potential for enhancing aerobic capacity, those with high level lesions (T3 and above) have a remaining obstacle to attaining higher work capacities: a level of pulmonary muscle denervation. The investigators preliminary work suggests this limits the aerobic capacity that can be achieved with FESRT.

External ventilatory support could improve the ability to exercise train and hence enhance the adaptations to chronic exercise in high level SCI. Non invasive ventilation (NIV) during exercise training has been shown to improve gains in exercise capacity in those with similarly restrictive breathing. Therefore, the investigators hypothesize that the use of NIV during FESRT will reduce ventilatory limits to exercise, leading to increased aerobic capacity in high level SCI. In addition, pharmacologic treatments may augment respiratory control and improve exercise ventilatory responses. Buspirone can reverse respiratory abnormalities consequent to SCI in rats, and humans case reports suggest successful Buspirone treatment of respiratory dysfunction

Therefore, the investigators propose a double-blind 2x2 trial of 6 months of FESRT with NIV or Sham and Buspirone or Placebo in individuals with acute, high-level SCI. The investigators hypothesize that both NIV and Buspirone will improve ventilatory exercise responses and that combined treatment will have the greatest effect. This will result in greater improvements in aerobic capacity and concomitant increases in pulmonary function and reductions in cardiometabolic risk. This work proposes two approaches to overcome ventilatory limitations to exercise in high level SCI and allow for greater improvements in cardiopulmonary capacity - one that overcomes mechanical limitations of paralyzed pulmonary musculature and one that treats loss of serotonergic respiratory control, both of which may contribute to blunted ventilatory responses. The ultimate purpose of this research is to optimize exercise for a population that both needs and seeks the broad range of benefits that exercise can confer.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Function Electrical Stimulation (FES)-Rowing
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCI outpatients aged 18-55 years
  • medically stable
  • 18.5-30 kg/m2 to include normal to overweight but not obese individuals
  • 3-months to 6-years post-injury
  • ASIA Scale A, B, or C injury at or above neurological level T4
  • able to follow directions
  • wheelchair users
  • leg muscles responsive to stimulation

Exclusion criteria

Exclusion Criteria:

  • BP >140/90 mmHg to exclude for hypertension (though rare in those with high level SCI)
  • current tobacco users
  • significant arrhythmias
  • coronary disease
  • diabetes
  • renal disease
  • cancer
  • epilepsy
  • current use of cardioactive medications (except medication to support blood pressure)
  • current grade 2 or greater pressure ulcers at relevant contact sites
  • other neurological disease
  • peripheral nerve compressions or rotator cuff tears that limit the ability to row
  • history of bleeding disorders
  • current use of buspirone
  • pregnancy
  • to Buspirone (taking MAO inhibitors, known to buspirone, benzodiazepine dependence, akathisia, renal impairment, hepatic disease)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    NIV + Buspar

    Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.

    Drug: Buspirone Hydrochloride · Device: Noninvasive Ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)

  • Placebo comparator
    NIV + placebo

    Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.

    Drug: Buspirone placebo · Device: Noninvasive Ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)

  • Sham comparator
    sham NIV + Buspar

    Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.

    Drug: Buspirone Hydrochloride · Device: Sham Non-invasive ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)

  • Active comparator
    sham NIV + placebo

    Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.

    Drug: Buspirone placebo · Device: Sham Non-invasive ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)

Interventions

  • DrugBuspironeStudies of BuspironeBuspirone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects take 30 mg buspirone HCl twice a day for 6 months.

    Also known as: Buspar

  • DrugBuspirone placebo

    Subjects take a placebo tablet twice a day for 6 months.

  • DeviceNoninvasive Ventilation (NIV)

    The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

  • DeviceSham Non-invasive ventilation (NIV)

    The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

  • OtherFunctional Electrical Stimulation Row Training (FESRT)

    Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.

06

What researchers measure

Primary outcomes

  1. Change in baseline aerobic exercise capacity

    Participants perform incremental FES rowing exercise test to determine maximum oxygen consumption (VO2 peak)

    Time frame: Baseline, 3 months, 6 months

  2. Change in baseline ventilation during exercise

    Participants perform incremental FES rowing exercise test to determine ventilation during exercise (VE peak).

    Time frame: Baseline, 3 months, 6 months

Secondary outcomes

  1. Change from baseline in glucoregulatory status

    Blood will be taken via standard venipuncture to measure the homeostasis model assessment (HOMA) of insulin resistance.

    Time frame: Baseline, 3 months, 6 months

  2. Change from baseline in glucoregulatory status

    Blood will be taken via standard venipuncture to measure the quantitative insulin check index (QUICKI).

    Time frame: Baseline, 3 months, 6 months

  3. Change from baseline in glucoregulatory status

    Blood will be taken via standard venipuncture to measure hemoglobin A1c.

    Time frame: Baseline, 3 months, 6 months

  4. Change from baseline in serum lipids

    Blood will be taken via standard venipuncture to measure plasma total cholesterol.

    Time frame: Baseline, 3 months, 6 months

  5. Change from baseline in serum lipids

    Blood will be taken via standard venipuncture to measure low-density lipoprotein cholesterol.

    Time frame: Baseline, 3 months, 6 months

  6. Change from baseline in serum lipids

    Blood will be taken via standard venipuncture to measure high density apolipoprotein cholesterol.

    Time frame: Baseline, 3 months, 6 months

  7. Change from baseline in serum lipids

    Blood will be taken via standard venipuncture to measure triglycerides.

    Time frame: Baseline, 3 months, 6 months

  8. Change from baseline in visceral adiposity

    The investigators will use a 5th generation General Electric Healthcare dual x-ray absorptiometry (DXA) scanner for regional fat measurements, the DXA software can be used to define standard regions that will allow comparability of measurements throughout the study.

    Time frame: Baseline, 3 months, 6 months

  9. Change in baseline forced vital capacity

    Spirometry will be used to measure lung function, specifically forced vital capacity (FVC).

    Time frame: Baseline, 3 months, 6 months

  10. Change in baseline maximal voluntary ventilation

    Spirometry will be used to measure lung function, specifically maximal voluntary ventilation (MVV).

    Time frame: Baseline, 3 months, 6 months

  11. Change in baseline forced expiratory capacity in the first second

    Spirometry will be used to measure lung function, specifically forced expiratory capacity in the first second (FEV1).

    Time frame: Baseline, 3 months, 6 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Apr 2026, 63 months.

Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's 63 months is above that.

Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Apr 2026 and completion Jul 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jul 7, 2020
StartActual
Dec 22, 2020
Primary completionActual
Apr 15, 2026was Jul 2026
CompletionEst.
Apr 15, 2027was Jul 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Apr 15, 2026 (actual)
Oct 16, 2026
Study completion
Jul 31, 2027→Apr 15, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Jul 31, 2026→Apr 15, 2026 (now actual)
    Study completion Jul 31, 2027→Apr 15, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04458324
Responsible party
J. Andrew Taylor (Director, Cardiovascular Research Lab, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Jul 7, 2020
Start date
Dec 22, 2020
Primary completion
Apr 15, 2026
Completion
Apr 15, 2027 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buspirone

Start the discussion